A surrogate-based re-estimation approach that conditions on all possible numbers of primary-endpoint discordant pairs using transition rates from the surrogate to the primary outcome is introduced.
Abstract
We develop blinded sample size re-estimation strategies for McNemar's test based on paired binary primary and secondary short-term surrogate endpoints. The development is motivated by a prospective randomized clinical trial on childhood glaucoma. A conditional power expression for McNemar's test given the primary endpoint at an interim analysis is derived and complemented by a sample size re-estimation rule. We show that this procedure preserves the type I error rate while allowing the second-stage sample size to be chosen to attain a prespecified target power. In the case where for some patients only a short-term surrogate endpoint is available at interim, we introduce a surrogate-based re-estimation approach that conditions on all possible numbers of primary-endpoint discordant pairs using transition rates from the surrogate to the primary outcome. We show how these transition rates can be estimated from data on a subsample for which both surrogate and primary endpoint are available. We derive the resulting surrogate endpoint-based conditional power and sample size rule and illustrate their use with the example of the motivating trial.
A flexible phase II design framework for two primary endpoints with nested response metrics is developed and the Holm-type and Holm-type designs can reduce the required sample size while maintaining prespecified error-rate and power requirements.
Jiangtao Gou, F. Zhang· Contemporary Clinical Trials· 0 citations
Electronic health record (EHR) phenotyping algorithms support clinical prediction, observational research, and quality improvement, but manual chart review for gold-standard validation is costly. For algorithms targeting rare outcomes, algorithm-negative patients often greatly outnumber algorithm-positive patients. We...
Rui Tang, M. Blasingame, Lillian Zheng et al.· 0 citations
Studies enrolling participants on the basis of an extreme baseline value are susceptible to regression to the mean (RTM), such that some observed pre-post change is expected even without treatment. Existing methods estimate and decompose RTM retrospectively. We extend this framework to prospective study design by deriv...
BACKGROUND
Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence fr...
C. Bommier, J. Dixon, M. Maurer et al.· Journal of Clinical Epidemio...· 0 citations
A new inference method for conducting multiple-treatment comparisons involving endpoints within the generalized linear model (GLM) framework under covariate-adaptive randomization (CAR) that can effectively control Type I error while potentially improving power.
Close-form links from sensitivity, specificity, and disease prevalence to predictive risks, risk contrasts, and Wald-type variance, power, and sample-size formulas for binary and fixed-horizon survival outcomes for binary and fixed-horizon survival outcomes are provided.
Yong-Qi Zhong, A. Hartman, Jing Zhang· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.